# CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

> **NCT01218867** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Cancer
- Metastatic Melanoma
- Renal Cancer

## Interventions

- **BIOLOGICAL:** Anti-VEGFR2 CAR CD8 plus PBL
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Aldesleukin
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT01218867
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11-10
- **Primary completion:** 2014-09-03
- **Final completion:** 2015-12-15
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** No objective responses were observed.
- **Last updated:** 2019-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218867, "CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01218867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*